Result of AGM, Issue of Equity & TVR

5 November 2026

Physiomics plc

("Physiomics" or the "Company")

Result of AGM

Issue of Equity, TVR, and Directors' Dealing

The Annual General Meeting of Physiomics was held today at 10.30 a.m. (GMT) at Strand Hanson, 26 Mount Row, Mayfair, London, W1K 3SQ. The Company is pleased to confirm that all resolutions put to shareholders were duly passed.

Full details of the poll results are set out below:

The number of shares in issue at 6:30 p.m. (UK) on 4 November 2026 was 453,208,718. The Company does not hold any shares in treasury.

Issue of Equity

As announced on 30 June 2026, the board of directors of Physiomics (the "Board" or the "Directors") agreed to receive new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in lieu of part of their cash remuneration.  Following the AGM, Nick Tulloch, Chairman, will be issued 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will be issued 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board.  

Admission and Total Voting Rights

Application has been made for 14,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 8:00 a.m. on 11 November 2026. The new Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares.

Following Admission, the Company's enlarged share capital will comprise 467,208,718 Ordinary Shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 467,208,718. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.